European Commission approves Yuflyma (adalimumab) biosimilar

Approval for treatment in 13 chronic inflammatory disease indications including RA, UC and psoriasis. Approval is based on analytical, preclinical and clinical studies which demonstrated Yuflyma is comparable to the reference product adalimumab, including efficacy and safety.

Source:

PharmaTimes